Doing immuno-oncology drug discovery means there is almost always a desire for more and different data to drive decision-making on potential new therapeutic compounds. That was exactly the situation one of our Fortune 500 pharmaceutical clients found themselves in.
Access to a top notch, outsourced group" that can perform studies to provide the data necessary to drive decision-making on proof-of-concept oncology agents.
“PharmaLegacy convinced us they had all the right pieces in place – and did the important work to validate the models that we hoped to run.”
“The study they delivered on a very reasonable budget was top notch” and “the model was executed flawlessly.”
To advance a compound from discovery to clinical, or to halt its development, is a huge and costly decision. For the benefit of you and your company, and for the well-being of patients in need of treatment, that decision needs to be based on correct information. Download the full case study and see why more major pharmaceutical companies are trusting PharmaLegacy for their preclinical immuno-oncology testing.
Some of the many reasons to partner with PharmaLegacy:
300+ validated animal models
Models spanning 40+ different diseases
Non-human primate (NHP) studies conducted on-site
Remote monitoring of operations